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Abstract
Glioblastoma, the most common primary malignant brain tumor, is incurable with current therapies. Genetic and molecular
analyses demonstrate that glioblastomas frequently display mutations that activate receptor tyrosine kinase (RTK) and Pi-3
kinase (PI3K) signaling pathways. In Drosophila melanogaster, activation of RTK and PI3K pathways in glial progenitor cells
creates malignant neoplastic glial tumors that display many features of human glioblastoma. In both human and Drosophila,
activation of the RTK and PI3K pathways stimulates Akt signaling along with other as-yet-unknown changes that drive
oncogenesis. We used this Drosophila glioblastoma model to perform a kinome-wide genetic screen for new genes required
for RTK- and PI3K-dependent neoplastic transformation. Human orthologs of novel kinases uncovered by these screens
were functionally assessed in mammalian glioblastoma models and human tumors. Our results revealed that the atypical
kinases RIOK1 and RIOK2 are overexpressed in glioblastoma cells in an Akt-dependent manner. Moreover, we found that
overexpressed RIOK2 formed a complex with RIOK1, mTor, and mTor-complex-2 components, and that overexpressed
RIOK2 upregulated Akt signaling and promoted tumorigenesis in murine astrocytes. Conversely, reduced expression of
RIOK1 or RIOK2 disrupted Akt signaling and caused cell cycle exit, apoptosis, and chemosensitivity in glioblastoma cells by
inducing p53 activity through the RpL11-dependent ribosomal stress checkpoint. These results imply that, in glioblastoma
cells, constitutive Akt signaling drives RIO kinase overexpression, which creates a feedforward loop that promotes and
maintains oncogenic Akt activity through stimulation of mTor signaling. Further study of the RIO kinases as well as other
kinases identified in our Drosophila screen may reveal new insights into defects underlying glioblastoma and related cancers
and may reveal new therapeutic opportunities for these cancers.
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Introduction
Glioblastoma (GBM), the most common primary malignant
brain tumor, infiltrates the brain, grows rapidly, and is refractory
to current therapies. Signature genetic lesions in GBM include
amplification, mutation, and/or overexpression of receptor tyro-
sine kinases (RTKs), such as EGFR and PDGFRa, as well as
activating mutations in components of the PI-3 kinase (PI3K)
pathway (reviewed in [1]). More than 40% of GBMs show EGFR
gene amplification, and these amplification events are often ac-
companied by mutations in EGFR [1]. The most prevalent
mutant form of EGFR is DEGFR (EGFRvIII, de2-7EGFR,
EGFR*), an intragenic truncation mutant that displays constitutive
kinase activity [2]. DEGFR and other constitutively active mutant
forms of EGFR found in GBMs potently drive tumor cell survival,
migration, and proliferation [2,3]. The most frequent mutation in
the PI3K pathway in GBM is loss of the PTEN lipid phosphatase,
which results in unopposed signaling through PI3K and robust
stimulation of Akt, especially in the context of EGFR activation
[1]. In mouse models, co-activation of these pathways in glia, glial
progenitor cells, and/or neuro-glial stem cells induces GBM
[4,5,6,7]. However, the full range of signaling events acting
downstream of or in combination with EGFR and PI3K to drive
oncogenesis remain to be determined. While several normal
effectors of RTK and PI3K signaling, such as Ras, Akt, and mTor,
are used by EGFR and PI3K in GBM and are required for
gliomagenesis [1], constitutive activation of RTK and PI3K
pathways may evoke changes distinct from those induced by
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normal developmental signaling. Notably, treatments with phar-
macologic inhibitors of EGFR or mTor are cytostatic at best in a
subset of patients, indicating that other, unidentified factors or
compensatory signals affect the survival and growth of tumor cells
[8].
To uncover new factors required for EGFR- and PI3K-
mediated gliomagenesis, we developed a GBM model in Drosophila
melanogaster [9]. Drosophila offers several advantages for modeling
cancers like GBM. Flies have orthologs for 75% of human disease
genes [10], including nearly all known gliomagenic genes;
signaling pathways are highly conserved; versatile genetic tools
are available for cell-type specific gene manipulation [11,12]; and
Drosophila neural cell types are homologous to their mammalian
counterparts [13,14]. While a Drosophila model cannot address all
aspects of human GBM, our model recapitulates important
pathologic features. Specifically, constitutive activation of EGFR-
Ras and PI3K signaling in Drosophila glial progenitor cells gives rise
to proliferative, invasive neoplastic glia that create transplantable
malignant tumors [9]. These tumors are induced through
activation of a synergistic genetic network composed of down-
stream pathways commonly mutated and/or activated in human
GBMs, such as Akt and mTor signaling [9]. However, activating
these known downstream pathways alone or in combination is not
sufficient to induce glial neoplasia in Drosophila, indicating that
additional, as yet unidentified, genetic pathways are involved in
transformation. Thus, we undertook genetic screens using our
Drosophila GBM model to discover new genes underlying EGFR
and PI3K mediated neoplastic transformation, and tested whether
human orthologs of the genes identified in Drosophila represent new
human genes involved in GBM.
Our analyses in both Drosophila and human systems uncovered
that the RIOK1 and RIOK2 kinases drive the survival and
proliferation of GBM cells. RIOK1 and RIOK2 are members of
the RIO (right open reading frame) family of atypical protein
kinases, named for yeast (S. cerevisiae) Rio1p and Rio2p,
respectively [15]. The RIOK1 and RIOK2 proteins are highly
conserved, and are present in all phylogenetic kingdoms, from
yeast to mammals among eukaryotes. Kinases in this family are
characterized by the presence of the RIO kinase domain, a kinase
fold structurally homologous to eukaryotic serine-threonine
protein kinase domains, but that lacks classic activation and
substrate binding loops (reviewed in [15]). While these kinases
undergo autophosphorylation and phosphorylate nonspecific
substrates in vitro, the actual in vivo substrates of RIO kinases are
unknown [15]. In both yeast and human cells, RIOK1 and
RIOK2, which are not functionally redundant, are required for
processing of the 18S rRNA and cytoplasmic maturation of the
40S ribosomal subunit, although neither kinase is an integral
component of the ribosome [16,17,18,19]. Recent studies demon-
strate that, in yeast, Rio2p also transiently associates with im-
mature ribosomes to block translation initiation, although how
RIOK2 is regulated in this context is unclear [20]. To date, several
studies have provided suggestive evidence that the RIO kinases
could be involved in RTK and PI3K signaling: RIOK2 becomes
rapidly phosphorylated in response to EGFR stimulation; Rio2p
binds to Tor2p, an ortholog of the mTor kinase, and RIOK1 is
required for the proliferation and survival of Ras-dependent
cancer cells [21,22,23]. However, to date, no specific function has
been ascribed to RIOK1 or RIOK2 in the context of EGFR or
PI3K signaling.
In this manuscript we demonstrate that RIOK1 and RIOK2
become overexpressed in GBM tumor cells relative to normal
brain cells; that RIOK1 and RIOK2 overexpression occurs in
response to constitutive Akt signaling; that RIOK2 forms a
complex with RIOK1, mTor, and other signaling components to
drive activation of Akt signaling and tumorigenesis; and that, in
GBM cells, RIOK1 or RIOK2 loss causes a reduction in Akt
signaling and provokes p53-dependent apoptosis, cell cycle exit,
and chemosensitivity through the RpL11-dependent ribosomal
stress checkpoint. Our data demonstrate that the RIO kinases play
a key role in Akt-mediated transformation of GBM cells.
Results
A kinome-wide screen for modifiers of glial neoplasia
To discover new genes involved in glial pathogenesis, we
performed a genetic screen using our Drosophila GBM model. Co-
overexpression of constitutively active forms of Drosophila EGFR
(dEGFRl) and the PI3K catalytic subunit p110a (dp110CAAX)
stimulates malignant transformation of post-embryonic larval glia,
inducing lethal glial neoplasia (Figure 1A–1C) (characterized in
detail in [9]). Using this larval Drosophila GBM model, we
performed an RNAi-based modifier screen for genes that suppress
(inhibit) or enhance (worsen) neoplastic phenotypes caused by
constitutive EGFR and PI3K signaling. In this scheme, which is an
enhancer-suppressor screen, modifier kinases that block/inhibit fly
glial neoplasia when their expression is reduced are referred to as
‘suppressors,’ and modifier kinases that exacerbate neoplasia when
their expression is reduced are referred to as ‘enhancers.’ This is in
keeping with standard Drosophila nomenclature, in which genes are
classified by their loss-of-function phenotypes. As a side-note, in
this context, the term suppressor does not refer to mammalian
tumor suppressors.
To enrich for new pathway components, we screened nearly all of
the kinases encoded in theDrosophila genome (Table S1). Our choice
to screen kinases was based on four considerations: (1) kinases
regulate a broad array of biological and cellular processes, including
those underlying oncogenesis; (2) kinases are highly conserved
between Drosophila and humans such that every Drosophila kinase has
a clear human ortholog; (3) as a group, they are well characterized,
facilitating functional analysis; and (4) drug discovery efforts are
focused on development of specific kinase inhibitors.
Author Summary
Glioblastomas, the most common primary brain tumor,
harbor mutations in receptor tyrosine kinases (RTKs), such
as EGFR, and components of the Pi-3 kinase (PI3K)
signaling pathway. However, the genes that act down-
stream of RTK and PI3K signaling to drive glioblastoma
remain unclear. To investigate the genetic and molecular
basis of this disease, we created a glioblastoma model in
the fruit fly Drosophila melanogaster. To identify new
genes involved in glioblastoma development, we per-
formed a screen for the genes required for tumor cell
proliferation using our Drosophila glioblastoma model and
then functionally assessed the activity of human versions
of novel genes identified in this screen. Our results
revealed that the RIO kinases become overexpressed in
human glioblastomas but not in normal human glial or
neuronal cells. We found that overexpression of the RIO
kinases promotes and maintains signals that drive tumor
cell proliferation and survival in RTK- and PI3K-dependent
human glioblastoma, and reduction of RIO kinase expres-
sion decreased proliferation and prompted cell death and
chemosensitivity in glioblastoma cells. Therefore, disrup-
tion of the RIO kinases may provide new therapeutic
opportunities to target glioblastoma and other RTK- or
PI3K-dependent cancers.
RIOKs in Glioblastoma
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Figure 1. A kinome-wide screen for modifiers of EGFR- and PI3K-dependent glial neoplasia. (A) Optical projections of whole brain-nerve
cord complexes from late 3rd instar larvae approximately 130 hrs old, displayed at the same scale. Dorsal view; anterior up. GFP labels glia (green).
Each brain is composed of 2 hemispheres and a nerve cord. Knockdown of strong suppressor loci decreased brain size, even relative to wild-type
controls, as in CG11859dsRNA;dEGFRl;dp110CAAX and CG11660dsRNA;dEGFRl;dp110CAAX animals. Glial-specific overexpression of DEGFR drives increased
glial cell numbers, brain enlargement, and lethality, and knockdown of strong suppressor loci grossly decreased brain size relative to controls, as in
CG11859dsRNA;DEGFR and CG11660dsRNA;DEGFR animals. (B–H) 3 mm optical projections of brain hemispheres from late 3rd instar larvae approximately
130 hrs old, displayed at the same scale. Frontal sections, midway through brains. Anterior up; midline to left. Glial cell nuclei labeled with Repo (red);
glial cell bodies labeled with GFP (green). Brains counter-stained with anti-HRP (blue), which reveals neuropil at high intensity and neuronal cell
bodies at low intensity. Dark areas contain unstained neuronal precursor cells. dEGFRl;dp110CAAX (C) and DEGFR (F) brains showed a dramatic increase
in glial cell number (red nuclei, green) relative to wild-type (B). Upon suppression, as in CG11859dsRNA;dEGFRl;dp110CAAX (D), CG11859dsRNA;DEGFR (G),
and CG11660dsRNA;DEGFR (H), there are few excess glia (red nuclei), and remaining glial cells show abnormal development (green). Reduction in both
glial (green) and neuronal cell types (low intensity blue) account for reduced brain size upon CG11660 and CG11859 knockdown in the context of
dEGFRl;dp110CAAX or DEGFR, which suggests that remaining abnormal glia do not properly support neuronal cell survival. Modifier constructs were
also tested for effects in wild-type glia, as in CG11859dsRNA animals (E). (I) Breakdown of screen results by kinases tested. Unconfirmed modifiers are
defined by only one RNAi construct each. (J) Functional classifications of confirmed modifiers. Individual kinases noted in Table S6.
doi:10.1371/journal.pgen.1003253.g001
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We tested 553 conditional RNAi constructs targeting 223 of the
243 kinases in the fly genome (Tables S1, S2) [24,25]. RNAi
constructs were expressed specifically within the glial lineage and
were tested for their phenotypic effects on proliferation, migration,
morphology, and/or viability of dEGFRl;dp110CAAX neoplastic
glia. The specificity of modifier loci was confirmed by testing
multiple RNAi constructs, dominant negative constructs, and/or
available mutant alleles to determine if they produced analogous
phenotypes in the dEGFRl;dp110CAAX model (Tables S2, S3).
Control assays were performed for the effects of modifier RNAi
constructs when expressed specifically in other cell types, including
normal glia, neuroblasts (Drosophila neural stem cells), and neurons
in order to distinguish those RNAi constructs that caused non-
specific toxicity from RNAi constructs that caused specific changes
in neoplastic glia (Table S4, Text S1). Constructs that caused early
organismal lethality in all cellular contexts tested were excluded
from analysis (Tables S2, S4).
To test whether modifiers act in oncogenic signaling down-
stream of specific EGFR mutations found in human GBM, we
created flies that overexpress human DEGFR. Glial-specific
expression of DEGFR caused lethal glial neoplasia phenotypes,
alone and in combination with dp110CAAX, that were similar to
dEGFRl, and these phenotypes required EGFR kinase activity
and core PI3K effectors, such as dAkt (Figure 1A–1F, Figure S1,
Table S5). We tested modifier RNAi constructs for the ability to
alter glial-specific DEGFR and DEGFR;dp110CAAX phenotypes
(Table S5); the results mirrored their genetic interactions with
dEGFRl;dp110CAAX (Table S2, S5), indicating that modifiers
identified in the screen are common to neoplastic phenotypes
conferred by both Drosophila and human EGFR.
We identified a total of 45 modifier genes (Figure 1I, Tables S2
and S3). Suppressor RNAi constructs targeting 39 genes reduced
neoplasia and induced smaller brain size and lower glial cell
numbers relative to dEGFRl;dp110CAAX controls, whereas enhanc-
er RNAi constructs targeting 6 genes worsened tumorigenesis and
neoplasia and induced increased glial cell numbers, and/or
aberrant glial morphologies (Figure 1A–1D, 1I, Tables S2 and
S3). Modifiers that suppressed glial neoplasia include genes
identified in previous studies, including dAkt [9] (Tables S2, S5).
A small subset of suppressor constructs caused strong phenotypes
in the context of constitutive EGFR-PI3K signaling. Constructs
targeting three modifier loci, Raf, Src42A, and Taf1, rescued
dEGFRl;dp110CAAX animals to adult viability, allowing neoplastic
glia to differentiate and function normally despite the presence of
dEGFRl and dp110CAAX (Table S2). Constructs targeting two of
the strongest modifiers, CG11660 and CG11859 (the Drosophila
orthologs of the RIOK1 and RIOK2 kinases, respectively), caused
severe reduction in brain size and glial cell number when
combined with dEGFRl;dp110CAAX, DEGFR;dp110CAAX, and/or
DEGFR, as compared to wild-type control animals (Figure 1A–1H,
Figure S1). dRIOK2 knockdown gave a stronger effect (Figure 1D,
1G). In contrast, RNAi constructs targeting dRIOK1 and
dRIOK2 did not produce a dramatic growth reduction when
targeted to normal glia (Figure 1E, Table S4), indicating that
dRIOK1 or dRIOK2 knockdown does not simply cause
nonspecific cellular toxicity.
Modifier kinases were classified by bioinformatic annotations
using Flybase, Gene Ontology, KEGG pathways, the STRING
database [26], and comparisons with other Drosophila RNAi
screens. These classifications (Figure 1J, Figure S2, Table S6) show
that kinases with core functions in the RTK and PI3K pathways
were highly represented, validating our model and screening
methodology [27,28,29]. Notably, very few of our modifiers have
emerged from Drosophila RNAi screens for cell viability (Table S7)
[30], indicating that most of the modifiers are not generically
required for cell survival. The largest group of modifiers have roles
in cell proliferation (Figure 1J, Table S6), and many of these
yielded reduced cell lineages upon knockdown in neuroblasts
(Table S4) [31], consistent with known requirements for RTK and
PI3K signaling in neural progenitor cells [9,32]. Several of the
modifiers involved in cell proliferation, such as warts (Table S2),
are also components of the hippo pathway, a pathway with a
documented role in glial cell proliferation [33]. Broad comparisons
with orthologs from species such as yeast (S. cerevisiae), revealed
modifiers kinases implicated in protein translation, such as
dRIOK1 and dRIOK2 [16,20], or in cell shape change and
migration. Finally, comparison to human kinases shows that the
majority of our modifier kinases have orthologs previously
implicated in GBM (Figure 1J, Figure S2, Table S7), leaving a
set of 16 novel modifiers, including dRIOK1 and dRIOK2.
Overexpression of RIOK kinases in human GBM correlates
with Akt activity
Novel modifier kinases identified in our Drosophila screens may
represent human kinases directly involved in GBM pathogenesis.
Kinases that block fly glial neoplasia when their expression is
reduced are of interest because their human orthologs may be
promising new targets for therapeutic inhibition. There are 27
human orthologs for the 16 novel Drosophila modifier kinases
(Table S8). To determine if any of these human kinases are
expressed or mutated in GBM, we analyzed tumor genomic
databases, proteomic atlases, and GBM cell lines, which provided
suggestive evidence that 12 modifier orthologs are subject to
genetic alteration and/or elevated gene or protein expression in
GBMs (see Text S1, Tables S9 and S10, Figures S3 and S4).
Among these, RIOK1 and RIOK2 showed increased protein
expression consistent with involvement in GBM. Given that loss of
the dRIOKs strongly and specifically blocks growth and survival of
EGFR and PI3K mutant glia, and that recent publications suggest
that the RIO kinases may contribute to EGFR and/or mTor
signaling [21,22], the functional roles of RIOK1 and RIOK2 in
GBM were of particular interest.
A range of GBM cells and cell lines were examined to determine
how RIOK1 and RIOK2 expression correlated with tumor cell
genotype and phenotype. Our analyses showed that RIOK1 and
RIOK2 were expressed in PTEN-null U87MG GBM cells and
were upregulated in U87MG cells engineered to express DEGFR
at levels detected in tumors [34] (Figure 2A). RIOK1 and RIOK2
were also upregulated in GBM tumors with EGFR overexpres-
sion/mutation as well as activated Akt (Figure 2B), although these
correlations were not clear in all specimens. Primary neurosphere
cultures, which are composed of neural stem cell-like human GBM
cells propagated in EGF-supplemented media [35,36,37], can
maintain mutations/gene expression found in their parent tumors
[37]. Neurosphere cultures showed strong RIOK1 and RIOK2
expression (Figure 2C); these included neurosphere lines with
DEGFR, as well as neurosphere lines displaying PDGFRa
overexpression, PTEN loss, and/or other mutant forms of EGFR
(Figure 2C). In a panel of standard GBM cell lines, RIOK1 and
RIOK2 showed strong expression in cell lines known to harbor
PTEN and/or EGFR mutations, and RIOK1 and RIOK2
expression was comparatively lower in a GBM cell line with
intact PTEN (Figure S5) [38,39]. In contrast, RIOK1 and RIOK2
were nearly undetectable in mixed glial cultures freshly derived
from adult human cortex (Figure 2D). Thus, RIOK1 and RIOK2
overexpression appeared to be correlated with RTK mutation/
overexpression and/or PTEN loss in GBM tumor cells.
RIOKs in Glioblastoma
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Figure 2. Expression of RIO kinases is associated with EGFR and Akt activity in GBM cells. (A) U87MG and U87MG-DEGFR cells cultured
with .1% serum for 36 hrs to enrich DEGFR signaling. DEGFR runs below full-length EGFR. (B) Biopsies of new (de novo) and recurrent GBMs. RIOK1
(,75 kDa) and RIOK2 (,63 kDa) antibodies used serially on the same blot. Serine-473 phosphorylation is a proxy for Akt activation. (C) Primary
RIOKs in Glioblastoma
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To determine if elevated RIOK1 and/or RIOK2 expression in
GBM cells depends on EGFR and/or PI3K signaling, neuro-
sphere lines and U87MG-DEGFR cells were treated with relevant
inhibitors (Figure 2E and 2G, Figure S6). RIOK1 and RIOK2
levels decreased upon either growth factor withdrawal or gefitinib
treatment of primary neurosphere cultures (Figure 2E), indicating
that their up-regulation can be EGFR-dependent. Consistent with
this, Pten2/2; Ink4a/arf2/2 mouse astrocytes transformed by
DEGFR showed increased RIOK1 and RIOK2 levels, which
were reduced by gefitinib treatment (Figure 2F). RIOK1 and
RIOK2 protein levels also decreased in neurosphere cells and
U87MG-DEGFR cells treated with inhibitors of the p110 PI3K
catalytic subunit, such as BEZ-235, and inhibitors of Akt, such as
A443654 (Figure 2G) [40]. siRNA-mediated Akt knockdown or
restoration of PTEN function in U87MG-DEGFR cells also
reduced RIOK protein levels (Figure 2H, Figure S7). Treatments
with p110 and Akt inhibitors also demonstrated that p110 and Akt
signaling is required for RIOK1 and RIOK2 expression in
PDGFRa-overexpressing neurospheres (Figure 2G). Taken to-
gether, these data indicate that RIOK1 and RIOK2 overexpres-
sion in GBM cells is driven by Akt activity downstream of RTK
mutation/overexpression and/or PTEN loss.
However, the role of factors that act downstream of Akt was less
clear (mTor inhibitors did not always reduce RIOK levels, see
Figure S6), suggesting that RIOK1 or RIOK2 levels may be
directly regulated by Akt. Given that mRNA expression levels of
RIOK1 and RIOK2 did not show significant upregulation in
tumor samples with PTEN and/or EGFR alterations (Table S9),
and given that RIOK1 and/or RIOK2 levels decline after short-
term treatments with Akt inhibitors (Figure S7), we hypothesized
that Akt signaling may regulate RIOK2 and/or RIOK1 levels by
modulating protein stability post-translationally. Consistent with
this, addition of a proteosome inhibitor, MG132, prevented the
reduction in RIOK1 and/or RIOK2 protein levels observed upon
A443654 treatment or PTEN add-back (Figure S7). RIOK2 has
several mapped serine phosphorylation sites (www.phosphosite.
org), including putative Akt target sites (Figure S8). However,
mutation of this single site did not abolish detection of RIOK2 by
a phospho-Akt-substrate antibody (Figure S9). Thus, Akt-mediated
regulation of RIO kinase levels does not hinge on phosphorylation
at a single residue in RIOK2, and likely involves a more complex
mechanism that requires more investigation.
To confirm that the RIOKs are expressed in GBM, we
performed immunohistochemistry (IHC) for RIOK2 on a group of
typed tumor specimens (RIOK1 antibodies were unsuitable for
IHC). Xenograft specimens of GBM39, which is DEGFR-positive
[41], showed RIOK2 expression in tumor cells, with cells
displaying diffuse cytoplasmic and sub-surface RIOK2 localization
(Figure 3A). In contrast, murine stromal cells had little or no
RIOK2 immunoreactivity, although the antibody can detect mouse
RIOK2. DEGFR-positive and EGFR-overexpressing specimens
displayed strong, but sometimes heterogeneous, cytoplasmic
RIOK2 immunoreactivity, ranging from the giant cell to the small
cell populations (Figure 3B–3E, Figures S10 and S11), with the
strongest expression in mitotic cells and densely cellular pseudo-
pallisades (Figure 3C and 3D, Figure S10). Heterogeneity in
RIOK2 expression may possibly reflect heterogeneity of RTK
expression in tumors [42,43], or may reflect upregulation of RIOK2
in actively cycling cells given the increased immunoreactivity
observed in mitotic cells. Cytoplasmic localization of RIOK2 in
GBM is consistent with observations of RIO kinase localization in
yeast and human cells [16,17,18]. In contrast, RIOK2 did not show
appreciable immunoreactivity in neural cells in matched normal
control brain (n= 14) (Figure 3F, 3H), and did not show
immunoreactivity in tumor stroma (Figure 3B), demonstrating that
RIOK2 upregulation is tumor-specific. Akt signaling in tumors was
assessed by staining for Akt phosphorylated at Serine-473 (Akt-
S473-P, example shown in Figure 3I), and EGFR status of tumors
was primarily assessed with staining for EGFR phosphorylated on
Tyrosine-1068 (EGFR-Y1068-P, example shown in Figure 3J),
which indicates EGFR activation. Statistical analysis demonstrated
that RIOK2 expression was significantly correlated with EGFR
status in tumor specimens (Figure 3L), although some EGFR-
negative tumors also showed RIOK2 immunoreactivity (Figure 3G,
3L), while some EGFR-negative tumors did not (Figure 3K). The
correlation of RIOK2 expression with EGFR activity is likely
secondary to Akt-mediated regulation of RIOK2: RIOK2-express-
ing specimens positive EGFR-Y1068-P always showed staining for
Akt-S473-P (n= 20). Indeed, all specimens that showed RIOK2
immunoreactivity, whether EGFR-positive or EGFR-negative,
showed staining for Akt-S473-P (Figure 3L).
RIOK2 overexpression in astrocytes induces invasive glial
tumors and TORC2-Akt activation
To determine if elevated levels of RIOK2 drives oncogenic
changes in mammalian cells, we tested the effects of RIOK2
overexpression in astrocytes. Pten2/2; Ink4a/arf2/2 murine astro-
cytes, which are immortalized by tumor suppressor mutations
common in GBM, express little endogenous RIOK2 and are not
gliomagenic in intracranial grafts assays [44]. In two experiments,
mice intracranially grafted with Pten2/2; Ink4a/arf2/2 astrocytes
overexpressing RIOK2 showed symptoms of hydrocephaly and
neurological deficits 3 weeks following implantation, unlike mice
grafted with Pten2/2; Ink4a/arf2/2 control astrocytes. Histological
analysis showed that control Pten2/2; Ink4a/arf2/2 astrocytes
yielded no intracranial tumors in 12 total animals tested, whereas
RIOK2overexpresion; Pten2/2; Ink4a/arf2/2 astrocytes formed invasive
high-grade glial tumors composed of invasive spindle-shaped cells in
7 out of 10 total animals tested (p,.001 by chi-squared test)
(Figure 4A, 4B).
In GBM, DEGFR drives strong Akt activation in the context of
PTEN loss, and can drive gliomagenic transformation of Pten2/2;
neurosphere GBM cultures. GBM39 is isolated from a DEGFR-positive serial xenograft [41]. Others are low-passage cultures established from fresh
tumors; expression of DEGFR, EGFR, or PDFGRa derives from parent tumors [35]. EGFRhw is a high molecular weight (.200 kDa) mutant version
detected in GBM 281. (D) RIOK expression and Akt signaling in neurospheres compared with a fresh culture of mixed human glia and astrocytes
(established from normal adult cortex) grown under the same conditions. (E) GBM301 treated for 24 hrs with growth factor withdrawl (.1% GFs, .1%
of the normal growth factor dosage) or 5 mM gefitinib. GBM301 cells are DEGFR-positive, EGFR-amplified, and PTEN-negative (see C). (F) Extracts from
PTEN2/2; Ink4a/arf2/2 astrocytes transduced with empty vector (left) or DEGFR (right), or grown with .5% serum and treated with gefitinib for 24 hrs
(far right). EGFR inhibition evidenced by reduced Tyrosine-1068 phosphorylation. (G) Neurosphere cultures treated for 24 hours with DMSO or
indicated inhibitors. P110 inhibitors: 50 mM LY294002, 1 mM BEZ-235, 2 mM GDC-0941 [71], 2 mM PI-103 [71]. Akt inhibitors: 1 mM A443654, 10 mM Akt
inhibitor IV [40], and 8 mM MK-2206 [72]. Inhibition of PI3K-Akt signaling evidenced by reduced phosphorylation of PRAS40, a direct Akt substrate,
and reduced Akt and/or PRAS40 protein levels. With A443654, increased Akt-Ser473 phosphorylation occurs despite Akt inhibition [40]; decreased
Akt-Ser473 phosphorylation occurs with Akt inhibitor IV and MK-2206 [72]. (H) U87MG-DEGFR cells treated with pan-Akt siRNAs compared to cells
treated with nontargeting control siRNAs, harvested 72 hours post-transfection.
doi:10.1371/journal.pgen.1003253.g002
RIOKs in Glioblastoma
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Figure 3. RIOK2 overexpression in GBM tumors is associated with Akt signaling. (A–E) Immunohistochemistry for RIOK2 (reddish brown)
showing cytoplasmic and submembraneous enrichment for RIOK2 in tumor cells. Hematoxilin counterstain, (A) GBM39 tissue, from a subcutanteous
xenograft, showing RIOK2 staining in tumor cells (arrows), which formed lobules delineated by RIOK2-negative host stromal cells. (B) DEGFR-positive
human GBM with RIOK2-positive giant cell component (inset shows a conspicuous giant cell), and RIOK2-negative tumor stroma composed of
abnormal blood vessels (‘‘BV’’). (C) DEGFR-positive human GBM, abnormal mitotic cells with high RIOK2 staining denoted with asterisks and shown in
inset close-up. (D) DEGFR-positive human GBM, lower magnification to highlight enriched RIOK2 in pseudopallisades (‘‘PSS’’), inset shows enriched
RIOK2 staining present in dense cellular regions of pseudopallisades. (E) RIOK2 expression in an EGFR-overexpressing human GBM with (F) matched
normal control tissue from the same surgical specimen, arrows denote normal astrocytes (recognized by their open nuclei). (G) RIOK2 expression in
an EGFR-negative/Akt-S473-P-positive GBM shown alongside (H) another example of normal control brain tissue. Arrows denote normal neuronal
cells (recognized by their basophilic cell bodies) with low/undetectable RIOK2 expression. (I) and (J) examples of Akt-S473-P and EGFR-Y1068-P
immunoreactivity in RIOK2-positive GBM tumor specimens. (K) a RIOK2- negative GBM with a negative abnormal blood vessel (‘‘BV’’). (L) Statistical
analysis of RIOK2-positive and negative tumor specimens showing a significant correlation between RIOK2 expression and phosphorylation of EGFR
at Tyrosine-1068 and phosphorylation of Akt at Serine-473. More stains from tumors shown in Figures S10 and S11.
doi:10.1371/journal.pgen.1003253.g003
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Figure 4. Overexpression of RIOK2 in murine astrocytes promotes tumorigenesis and TORC2-Akt signaling. (A) H&E stain showing
high-grade glioma derived from RIOK2overexpression; Pten2/2; Ink4a/arf2/2 astrocytes grafted into the mouse brain. Tumor cells (purple) generate
masses composed of spindle-shaped cells as well as infiltrative neoplastic cells that show invasion into the parenchyma and along blood vessels,
animals sacrificed ,19 days following injection. (B) representative needle tract (arrows) in a mouse brain grafted with control Pten2/2; Ink4a/arf2/2
astrocytes engineered with empty vector; note the slight concentration of astrocytic cells along the needle tract but no tumor mass or infiltrates. (C)
Western blots of RIOK2overexpression; Pten2/2; Ink4a/arf2/2 astrocytes compared to Pten2/2; Ink4a/arf2/2 astrocytes with empty vector, grown in vitro.
(D) Immunoreactivity for Akt phosphorylated at Serine-473 (reddish brown) in a tumor derived from RIOK2overexpression; Pten2/2; Ink4a/arf2/2
astrocytes, tumor margin shown, with many surrounding normal cells (purple nuclei, faint staining). Arrow indicates strong staining in invasive cells at
tumor margin, asterisk indicates more distant individual invasive cells; both shown in close-up (right). (E) Epitope tagged RIOK2 (RIOK2-flag, runs
slightly larger than endogenous untagged RIOK2) was overexpressed in 293T cells and immunoprecipitated along with associated proteins. Blots
were probed for indicated proteins, whole lysates from both before (pre-IP) and after (post-IP) are included as a control for protein expression.
doi:10.1371/journal.pgen.1003253.g004
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Ink4a/arf2/2 astrocytes [6,45]. Thus, we wondered whether
RIOK2 overexpression also drives astrocyte transformation by
activating Akt. Consistent with this, RIOK2overexpression; Pten2/2;
Ink4a/arf2/2 astrocytes displayed increased phosphorylation of Akt
at Serine-473 (Figure 4C), and tumor tissue from RIOK2overexpression;
Pten2/2; Ink4a/arf2/2 cells showed specific staining for Akt-
Ser473-P (Figure 4D). Phosphorylation of Serine-473 is required
for Akt activity towards select substrates such as FOXO3 [46], a
direct Akt substrate that governs GBM cell tumorigenicity [47].
FOXO3 also displayed increased phosphorylation RIOK2overexpression;
Pten2/2; Ink4a/arf2/2 astrocytes (Figure 4C). However, we did not
observe increased phosphorylation of all Akt targets, including
PRAS40, with RIOK2 overexpression, suggesting that the effect of
RIOK2 on phosphorylation of Akt targets was selective to Serine-
473 dependent substrates [46].
Akt is phosphorylated on Serine-473 by mTor-complex-2
(TORC2), a multi-protein complex composed of the mTor kinase
and several other signaling components, including Rictor [46], a
protein that becomes elevated in glioblastomas that also drives
gliomagenesis when overexpressed in astrocytic cells [48,49]. In
yeast proteomic analyses, Rio2p has been shown to bind to Rio1p
and Tor2, the yeast mTor ortholog that forms the equivalent of
TORC2 [22]. From human cells overexpressing RIOK2, RIOK2
co-immunoprecipitated with RIOK1, mTor, and Rictor, a protein
which is definitive of the TORC2 complex (Figure 4E) [46]. mTor
also associates with another complex, mTor-complex-1 (TORC1),
which phosphorylates other mTor substrates, such as EIF-4E,
and is composed of signaling components including the Raptor
protein [46]. Raptor did not co-immunoprecipitate in the RIOK2-
RIOK1-mTor-Rictor complex (Figure 4E), suggesting that
RIOK2 specifically associates with TORC2. Taken together,
these data suggest that RIOK2 directly binds to TORC2 to
stimulate phosphorylation of Akt at Serine-473 and activation of
Akt towards select substrates, such as FOXO3, and that this
process may directly involve RIOK1 recruitment.
Requirement for RIOK kinases for proliferation and
survival in GBM cells
Given that knockdown of their Drosophila cognates yields growth
reduction of neoplastic glia, we tested RNAi constructs targeting
human orthologs of novel suppressor kinases for their requirement
in GBM cell survival and proliferation (Text S1, Figure S12).
Among these, RIOK1 or RIOK2 knockdown yielded strong
effects, inhibiting U87MG-DEGFR and U87MG proliferation
(Figure 5A, 5B). DEGFR-positive neurosphere cultures, such as
GBM301 and GBM39, also showed a pronounced apoptotic
response to RIOK2 or RIOK1 knockdown, with RIOK2 loss
yielding stronger effects (Figure 5C, 5D). In U87MG cells, which
are dependent on Akt signaling for growth [50], RIOK1 or
RIOK2 RNAi provoked G2 cell cycle arrest and reduced
proliferation (Figure 5A–5B). The phenotypes caused by RIOK1
and RIOK2 knockdown were observed in other GBM cell lines
that are PTEN and/or EGFR mutant, such as A172 (Figure 6,
Figure S14, data not shown). Of note, RIOK2 knockdown
typically triggered a reduction in RIOK1 expression, regardless of
the RIOK2 RNAi constructs used, suggesting that RIOK2
regulates RIOK1 protein levels (Figure 5D, Figure S13, see also
Figure 6).
Given that the RIO kinases have been found to stimulate
ribosome maturation, we initially suspected that functional
reduction of RIOK1 or RIOK2 may cause generic cellular
toxicity. However, in testing multiple GBM cell lines that showed
strong RIOK expression, we found that a subset of GBM cells
were far less affected by knockdown of RIOK1 and RIOK2.
GBM6, a DEGFR-positive neurosphere line, did not undergo
apoptosis upon RIOK1 or RIOK2 knockdown (Figure 5D).
Moreover, LNZ308 cells, which are PTEN mutant [38], did not
show cell cycle defects or strong reduction of RIOK1 expression
with RIOK2 knockdown (Figure 5B). Both GBM6 and LNZ308
are also mutant or null for p53, whereas GBM cells that show cell
cycle defects and apoptosis upon RIOK loss, such as U87MG, are
wild-type for p53 [38,41]. We observed a similar lack of apoptosis
upon RIOK1/RIOK2 loss in other p53 mutant/null GBM cells,
such as U373 (data not shown). This implies that the survival and
proliferation defects induced by RIOK1 and RIOK2 loss rely on
p53. Consistent with this, concomitant knockdown of p53 with
RIOK1 or RIOK2 in U87MG cells blocks the apoptosis observed
upon RIOK2 or RIOK1 knockdown alone (Figure 5E).
In human cells, RIOK1 and RIOK2 transiently associate with
immature cytoplasmic 40S ribosomal subunits to promote their
maturation and stimulate rRNA processing, like their yeast
counterparts [18,19,22,51]. Defects in ribosome biogenesis and
rRNA processing can activate a p53-dependent ribosomal-stress
checkpoint to suppress growth and induce cell cycle arrest and
apoptosis, a process that relies on p53 upregulation and tran-
scriptional activation mediated by release of the RpL11 ribosomal
protein (reviewed in [52,53]). In U87MG cells and other GBM cell
lines, RIOK1 or RIOK2 knockdown induced up-regulation of
p53 and the p21 cdk inhibitor, a p53 transcriptional target
(Figure 5F, Figure S13, S14), and coincident knockdown of RpL11
and RIOK1 or RIOK2 blocked induction of p53 and p21
(Figure 5F and Figure S14). Therefore, RIOK1 or RIOK2 loss
leads to p53 activation, which requires the p53-RpL11-dependent
ribosomal stress checkpoint.
Loss of RIOK function chemosensitizes GBM cells in a
p53-dependent manner
p53 is often downregulated in GBM tumors and tumor cells
with activated Akt, PTEN loss, and/or EGFR mutation/
overexpression [54]. Yet, the majority of tumors with PTEN loss
or EGFR mutation/amplification have intact p53 loci (EGFR: 85–
92%, PTEN: 92–95%) [55,56]. Given that RIOK loss upregulates
p53 levels, we tested whether knockdown of RIO kinases could
potentiate the response of GBM cells to treatments with DNA-
damaging agents such as doxorubicin, which cooperates with p53
to provoke apoptosis, [57,58] and temozolomide, which is a DNA
alkylator used to treat GBM. In GBM cells wild-type for p53, such
as GBM301 and U87MG, knockdown of RIOK1 or RIOK2
potentiated apoptotic responses to doxorubicin and/or temozolo-
mide (Figure 6A–6B, Figure S15). In contrast, cells mutant for
p53, such as LNZ308 cells, did not show apoptosis upon RIOK1
or RIOK2 knockdown and doxorubicin-temozolomide treatments
(Figure 6A). Therefore, inhibition of the RIO kinases chemosensi-
tizes EGFR- and/or PTEN mutant GBM cells.
Our results suggest that elevated p53 activity can potentiate
elimination of EGFR and/or PTEN mutant GBM cells. One way
to increase p53 levels and activity is with nutlin-3, a small molecule
which is know to cause cell cycle arrest and sensitivity to DNA-
damaging agents in U87MG cells [59]. However, nutlin-3 did not
provoke the same cell cycle defects observed with RIO kinase
knockdown, despite inducing high levels of p53 and p21 (Figure
S16). Thus, other changes induced by RIO kinase loss must
contribute to cell cycle arrest and apoptosis.
Loss of RIOK function antagonizes Akt signaling
We tested for signaling alterations that occur upon RIOK1 or
RIOK2 knockdown that would explain reduced proliferation and
survival of GBM cells. The caspase inhibitor ZVAD was used to
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dampen apoptosis and thus preserve signaling defects. Compared
to controls, RIOK1 or RIOK2 knockdown led to reduced
phosphorylation of Akt at Serine-473 and reduced phosphoryla-
tion of Akt target proteins such as FOXO3 (Figure 6C, Figure
S17). This occurred in both p53 wild-type and p53 mutant GBM
cells (Figure 6C, Figure S17). Serine-473 is phosphorylated by
Tor complex 2, (TORC2) [46], and in yeast and human cancer
cells, TORC2 phosphorylation of Akt is stimulated by mature
ribosomes, which can bind to both TORC2 and Akt to mediate
their interaction, and TORC2 activity is blocked by defects in
ribosome biogenesis [60]. Given that RIOK1 and RIOK2 loss
causes defects in 40S ribosome maturation [17,18,19], and that we
discovered that RIOK1 and RIOK2 bind to TORC2 compo-
nents, we hypothesized that RIOK1 and RIOK2 knockdown
interferes with TORC2 activity. Consistent with this, other rea-
douts of TORC2 activity, such as phosphorylation and levels of
NDRG1 [60], were reduced (Figure 6C, Figure S17), demon-
strating that TORC2 activity is downregulated by RIOK1 and
RIOK2 loss. This is consistent with recent findings demonstrating
a requirement for TORC2 signaling in Drosophila glial neoplasia
as well as human GBM cells [9,48,49]. However, the effects of
RIOK loss on Akt signaling were not limited to the TORC2-
dependent substrates. Phosphorylation of other Akt substrates,
such as PRAS40 and TSC2, can also be reduced upon RIO kinase
knockdown (Figure 6C). Thus, RIOK1 and RIOK2 are necessary
for Akt signaling in GBM cells. Over-all, our results strongly
suggest that functional reduction of RIOK1 and RIOK2 results in
loss of Akt activity and p53 activation to drive cell cycle arrest,
chemosensitivity, and apoptosis in Akt-dependent GBM cells with
intact p53 (Figure 7).
Discussion
From a Drosophila genetic screen, we identified genes encoding
16 novel kinases that affect EGFR- and PI3K- dependent
neoplastic glial transformation. We found that a subset of human
orthologs for these novel kinases, including RIOK1 and RIOK2,
are subject to alterations in GBM. RIOK1 and RIOK2, two
related and highly conserved atypical kinases, become upregulated
in an Akt-dependent manner in GBM cells. Our results show that
RIOK2 forms a complex with RIOK1 and TORC2 signaling
components, drives activation of TORC2-dependent Akt signal-
ing, and stimulates glial tumorigenesis. Furthermore, we found
that, in GBM cells, RIOK1 or RIOK2 loss causes a reduction in
Akt signaling towards TORC2-depdendent targets and provokes
p53-dependent apoptosis, cell cycle exit, and chemosensitivity.
Thus, our loss-of-function and gain-of-function data imply that
RIOK2 creates a feedforward loop that promotes and maintains
Akt activity, and disruption of this loop is sufficient to trigger
chemosensitivity and apoptosis in Akt-dependent GBM cells with
intact p53 (Figure 7). Our results may have broad relevance to
other cancers since RIOK2 is strongly expressed in a range of
other more common tumor types associated with high Akt activity,
such as breast and prostate cancers (Figure S18). Further study of
the RIO kinases as well as other kinases identified in our Drosophila
screen may reveal new insights into the signaling defects
underlying GBM and related cancers.
RIOK1 and RIOK2 upregulation was associated with Akt
activity in both GBM tumor specimens and cultured cells, and our
results show that Akt signaling regulates RIO kinase protein
stability, although the exact mechanism by which Akt regulates
RIO kinase levels remains undetermined. RIOK2 has several
putative and mapped phosphorylation sites, including at least one
putative Akt phosphorylation site (www.phosphosite.org, Figure
S8). Other studies show that RIOK2 phosphorylation can be
stimulated by EGFR, and can be carried out by Polo-like kinase 1
[21,61], and perhaps these events contribute to Akt-mediated
regulation of RIO kinase levels. Of note, though standard GBM
cells lacking PTEN showed high levels of RIO kinase expression,
non-transformed astrocytes lacking PTEN did not show high levels
of endogenous RIO kinase protein expression relative to astrocytes
with intact PTEN. Therefore, other factors present in GBM cells
must also contribute to elevated RIO kinase levels.
To date, published studies show that the RIO kinases act as
ribosome assembly factors that transiently associate with the 40S
subunit to promote ribosome maturation and translation initiation
[17,18,20]. Given that mature ribosomes are required for TORC2
activation and Akt phosphorylation at Serine-473 [60], disruption
of Akt signaling upon RIOK knockdown may be a result of
defective ribosome biogenesis caused by RIO kinase loss. How-
ever, the RIO kinases may have a much more direct role in
promoting and maintaining Akt activity given that RIOK2 binds
to RIOK1 and to components of the TORC2 complex, which is
consistent with recent studies in yeast showing that Rio2p can bind
to Tor2 [22]. Given that Rio2p is released from mature ribosomes
in a regulated process [20], it is possible that the reason mature
ribosomes promote TORC2 signaling is because they release free
cytoplasmic RIOK2 that then stimulates TORC2 assembly or
activity. The specific interplay between the RIO kinases and mTor
signaling, ribosome biogenesis, protein translation, and Akt
signaling will require additional investigation in the context of
both normal and abnormal PI3K and RTK signaling, and may
involve other as yet undetermined factors.
Although RIOK1 and RIOK2 loss can cause defects in
ribosome maturation [17,18], in GBM cells the effects of RIO
loss are not generic and instead are genotype-specific: p53 null
mutant GBM cells showed no major cell cycle defects or apoptosis
upon loss of these kinases. This specificity is derived from p53
upregulation and activation induced by the RpL11 ribosomal
protein in response to RIOK loss. In humans, activation of the
Figure 5. RIOKs drive proliferation and survival of GBM cells in a p53-dependent manner. (A) WST-1 assays. Following selection for shRNA
expression, proliferation was measured with WST-1 reagent and quantified as the fold increase in absorbance between day 0 and day 3, normalized
to controls treated with a nontargeting shRNA. 2 shRNAs tested per RIO kinase. P values refer to one-way ANOVA with Dunnett post test. Knockdown
verified in Figure S13. (B) FACS analysis of cell cycle. Fixed cells were stained with propidium iodide for DNA content 72 hrs after siRNA transfection.
Knockdown verified in Figure S13. (C, D) RIOK1 or RIOK2 knockdown stimulated apoptosis of neurosphere cultures, such as GBM39 and GBM301
(brightfield, D), evidenced by apoptotic features (D) and PARP cleavage, which indicates pro-apoptotic caspase activity (PARPfl indicates full-length
PARP, PARPcl indicates cleaved PARP, in both long and short exposures). RIOK1 or RIOK2 knockdown did not significantly stimulate apoptosis in p53-
mutant cells, such as GBM6, evidenced by lack of significant PARP cleavage. DEGFR-positive: GBM39, GBM301, and GBM6. PTEN-mutant: GBM301.
PTEN-intact: GBM39 and GBM6. Cells harvested 96 hrs post-lentiviral infection. (E) Annexin V staining for apoptosis in U87MG cells, quantified by
FACS. Controls (left) were treated with equivalent amounts of nontargeting control siRNAs alone (light blue) or control siRNAs mixed 1:1 with p53
siRNAs (dark blue). RIOK1 and RIOK2 siRNAs were mixed 1:1 with control (light blue) or p53 siRNAs (dark blue). Data is represented as the fold change
in Annexin V-positive cells in the RIOK knockdown samples compared to corresponding control samples. Knockdown verified in Figure S13. (F) RIOK1
or RIOK2 knockdown upregulates p53 and p21 expression, which is blocked by concurrent RpL11 knockdown. For RpL11 experiments, cells were
treated with equivalent amounts of siRNAs mixed 1:1 for control and experimental samples. Cells were harvested 72 hrs post-transfection.
doi:10.1371/journal.pgen.1003253.g005
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Figure 6. Loss of RIOK1 or RIOK2 function chemosensitizes GBM cells and reduces TORC2-Akt signaling. (A) Knockdown of RIOK1 or
RIOK2 sensitizes GBM cells to apoptosis in response to treatment with doxorubicin (doxo) and temozolomide (tmz), as evidenced by blots for active
caspase-3 and PARP cleavage (A). All samples blotted for RIOK1 and RIOK2 to confirm changes in RIOK1 levels with RIOK2 knockdown, evident in p53-
wild-type GBM cell lines. The RIOKs also decline with doxorubicin treatment. GBM301 cells were treated for 24 hrs with 1 mg/mL doxorubicin
beginning 96 hrs post infection with viral vectors. U87MG, A172, and LNZ308 cells were treated for 24 hrs with 1 mg/mL doxorubicin and 100 mM
temozolomide beginning 72 hrs post transfection with siRNAs. (B) FACS-based quantification of chemosensitivity. 96 hours post shRNA infection,
U87MG samples were split in half and treated for 12 hours with either DMSO (light blue) or 1 mg/mL doxorubicin and 100 mM temozolomide (red).
Live cells were collected and stained for 7AAD and Annexin-V. Data is represented as the percentage of Annexin V-positive 7AAD-negative cells in
each sample, averaged over 2 experiments. P-values refer to student’s two-tailed t-test used to compare doxorubicin and temozolomide-treated
control to RIOK-shRNA cells. Validation of knockdown shown. FACS plots and raw data shown in Figure S15. (C) GBM301 cells treated with 25 mM
ZVAD for 48 hrs beginning 3 days post-infection with viral vectors. Reduced phosphorylation of Akt on the TORC2 target site, Serine-473, is visible
relative to total Akt protein. Reduced phosphorylation of several Akt targets, such as the FOXO3 transcription factor, is clear when phospho-epitope
signal is compared to total protein controls. PARP cleavage is a read-out for apoptosis; PARP cleavage fragment in RIOK2 knockdown cells indicates
residual caspase activity, due to the strong effect of RIOK2 loss. p53 upregulation was evident in GBM301 cells in the absence of residual caspase
activity.
doi:10.1371/journal.pgen.1003253.g006
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RpL11-p53-dependent ribosomal-stress checkpoint is associated
with diseases caused by ribosomal protein haploinsufficiency,
such as Diamond-Blackfan anemia, which are characterized by
stem and progenitor cell failure [52,53]. Similarly, in Drosophila,
haploinsufficiency of genes that encode ribosomal proteins retards
developmental cell proliferation [62]. Given that cancer cells share
many properties with stem and progenitor cells, induction of
the RpL11-p53 ribosomal stress checkpoint may prove useful
to deplete cancer cells. Indeed, recent experimental evidence
indicates that the RpL11-p53-dependent ribosomal stress check-
point suppresses tumorigenesis in mouse cancer models [63].
Moreover, several chemotherapeutic drugs induce the ribosomal
stress checkpoint [64,65]. However, many of these drugs have
deleterious effects unrelated to ribosomal stress, limiting their use.
More specific induction of the ribosomal stress checkpoint,
perhaps through RIO kinase inhibition, may prove therapeutically
useful for GBM as well as related cancers.
The importance of RIO kinases in cancer cell survival has been
validated in independent studies. RIOK2 was recently identified in
an RNAi-based screen for kinases that are required for survival of
glioma stem-like cells, which confirms our results, although the
functionality of RIOK2 in glioma was not explored [66]. In
addition, RIOK1 was identified in a cell-based RNAi screen for
genes required for Ras-mediated cell survival, although the
functionality of RIOK1 was not explored in this study [23]. Of
note, almost all other published cell culture-based RNAi screens in
GBM cell lines did not pick up RIOK1 or RIOK2 because these
screens were not designed to distinguish between kinases that were
required for genotypic-specific survival or growth of GBM cell
lines, and instead focused on kinases that showed a common
requirement in all glioblastoma cell lines tested, be they mutant or
wild-type for p53, EGFR, or PTEN [67,68,69]. Our results, which
are derived from independent multidisciplinary assays, are the first
to establish functional connections between the RIO kinases,
oncogenesis, Akt signaling, and the RpL11-p53-dependent ribo-
somal stress checkpoint (Figure 7). We envision that RIOK loss-of-
function phenotypes in GBM cells are due to the combined effects
of Akt inhibition and p53 induction, which together stimulate
apoptosis and cell cycle exit of EGFR- and PTEN- mutant GBM
cells, which share a common dependence on Akt signaling
(Figure 7). Further studies to address the mechanisms by which
the RIO kinases modulate Akt and p53 activity may lead to
important new insights into the interactions between both of these
pathways in both normal and cancer cells.
Materials and Methods
Fly stocks, genetics, culture conditions,
immunohistochemistry, and gefitinib treatment
Flies were cultured at 25uC unless otherwise noted. Genotypes
were established by standard genetics. Larval brain phenotypes
were assessed and imaged as previously described [9]. Stocks were
obtained from VDRC, NIG, and Bloomington stock centers
(Table S1). wor-Gal4 lines were from C. Doe. To create UAS-
DEGFR constructs, a full-length human DEGFR cDNA was
cloned into pUAS-T, and fly stocks with stable insertions were
created.
The screen was based on crosses (see Text S1 for genetic
methodology) that generated progeny containing a single RNAi
construct exclusively expressed in GFP-labeled glia along with
dEGFRl and dp110CAAX. Transgenes were overexpressed using
the glial-specific repo-Gal4 transcriptional driver. Screening was
performed using fluorescence microscopy to visualize GFP-labeled
glia in living larvae, and phenotypes were confirmed with confocal
microscopy. Each positive-scoring RNAi construct was tested at
least twice. Positive scoring RNAi constructs were also tested in
wild-type glia, neuroblasts, and neurons (Text S1, Table S4)
Mammalian tissue culture techniques and RNAi
Established primary neurosphere cultures (gifts of H. Korn-
blum) were maintained as previously described in DMEM/F12
medium supplemented with bFGF and EGF [35,41]. Neurosphere
cultures of GBM39 and GBM6 were created from serial
xenografts of human GBMs (gifts of C.D. James). Cultured
normal human glia were derived from a fresh surgical specimen of
normal human cortex (gift of J. Olson) procured under a protocol
approved by the Emory University institutional review board.
Cultured mouse PTEN2/2; Ink4a/arf2/2 astrocytes (gift of R.
Bachoo) were maintained in DMEM with 10% serum. The
Figure 7. RIOK1 and RIOK2 are required for EGFR- and PI3K-mediated tumorigenesis. Pathway diagram placing RIOK1 and RIOK2 in
relation to Akt downstream of EGFR and PI3K signaling in GBM. RIOK2 mediates signaling both upstream and downstream of Akt via stimulation of
TORC2 (left). Loss of RIOK1 or RIOK2 reduces Akt signaling downstream of oncogenic EGFR and PI3K signaling, and induces the p53-dependent
ribosomal stress checkpoint via RpL11 (right).
doi:10.1371/journal.pgen.1003253.g007
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RIOK2 cDNA (Origene) was overexpressed in PTEN2/2; Ink4a/
arf2/2 astrocytes from the pBabe retroviral vector.
The following drugs were used: Nutlin-3 (Cayman), MG132,
Akt inhibitor IV (Calbiochem), temozolomide (Tocris), doxorubi-
cin, rapamycin, PP242 (Santa Cruz), PI-103, ZVAD (Enzo),
A443654 (gift of Greg Riggins), gefitinib (LC Laboratories), BEZ-
235 (Biovision), LY294002 (Cell Signaling Technology), MK-
2206, and GDC-0941 (Selleck). Doses of LY294002, BEZ-235,
PI-103, GDC-0941, and MK-2206 used on GBM cells were
determined by using dose response assays to find the concentra-
tions at which cells showed substantial reduction (approximately
,20% of normal) in Akt-mediated phosphorylation of PRAS40 (as
detected by immunoblot).
Lentiviral shRNA pLKO.1 plasmids were obtained from the
Broad Institute of MIT. RIOK1 shRNAs: TRCN0000196278
and TRCN0000196981. RIOK2 shRNAs: TRCN0000197250,
TRCN0000196672, and TRCN0000196684. pLKO.1-GFP and
a nontargeting shRNA against lacZ (in pLKO.1) were used as
controls. Lentivirus was produced and used as per standard
protocols (Sigma). Knockdown was evident by western blot 96 hrs
post-infection. For neurosphere cultures, lentivirus was prepared
in DMEM/F12 without serum, and infections were done on cells
were plated adherently [36].
For siRNAs, all constructs were transfected at 50–100 mM with
RNAimax (Invitrogen). Unless otherwise noted, siRNA-treated
cells were harvested at 72 hrs post-transfection. 2 sets of pooled
siRNAs were tested each for RIOK1 and RIOK2 (Dharmacon),
and two different nontargeting siRNAs against GFP or luciferase
were used as controls (Dharmacon). For knockdown of p53, p53
siRNAs were used and compared to matched control nontargeting
siRNAs (Cell Signaling Technologies). Target sequences are listed
in Text S1. For dual-knockdown experiments, U87MG cells were
preferred because, with the necessary higher doses of siRNAs,
U87MG-DEGFR cells showed nonspecific alterations in DEGFR
expression that affected RIOK levels.
Immunoblot analysis
Cells were lysed in RIPA buffer and cleared lysates were
subjected to standard immunobloting. The following primary
antibodies were used: RIOK1 (Novus), RIOK2 (Sigma), p53
(Santa Cruz), p21, EGFR (BD), actin (DSHB), RpL11 (Invitro-
gen), NRBP2 (Abcam), STK17a/DRAK1 (Anaspec), PDGFRa,
VRK1, CDK9, CDK7, STK17B/DRAK2, TLK1, phospho-
Akt(S473), phospho-Akt(T308), phospho-PRAS40(T246), phos-
pho-FOXO1(T24)/FOXO3(T32), Akt, phospho-NDRG1(T346),
NDRG1, PRAS40, phospho-4E-BP1, 4E-BP1, PARP, cleaved
caspase, FOXO3, TSC2, phospho-TSC2, mTor, phospho-mTor
(T2448) (Cell Signaling Technologies)
WST1 and FACS assays
For WST-1 assays, cell lines were infected with lentiviral
shRNA constructs and placed under selection for 48 hrs.
Following selection, cells were plated for WST1 assays for cell
proliferation/viability as per manufacturer’s instructions (Clon-
tech). For flow cytometry (FACS) analysis of DNA content, cells
were dissociated and stained with propidium iodide (PI). For
FACS analysis for apoptosis, cells were treated with indicated
siRNAs or lentiviral vectors and stained with Annexin V-FITC
and PI or 7AAD (Invitrogen, BD Biosciences). Assays were
performed on a FACScaliber II flow cytometer and data were
collected using FACSdiva software (BD Biosciences). Cell cycle
profiles were generated using ModFit LT (Verity Software House).
In all cases, at least 5000 cells were analyzed per sample.
RIOK2 overexpression and immunoprecipitation
293T cells were transiently transfected with Myc-DDK-tagged
RIOK2 constructs. Cells were lysed in 50 mM HEPES pH 7.5,
150 mM NaCl, 5 mM EDTA, 1 mM DTT buffer with protease
and phosphatase inhibitors [22]. RIOK2 was immunoprecipitated
with M2-agarose (Sigma) from cleared lysates, and washed im-
munoprecipitates were subjected to immunobloting.
Biopsy lysates and immunohistochemistry on tumor
samples
Human brain tumor biopsies and tissues were obtained from the
Brain Tumor Translational Resource under a protocol approved
by the University of California, Los Angeles institutional review
board. Paraffin embedded human brain tumor specimens and
tumor tissue microarrays with matched control tissue were
prepared and sectioned using the UCLA Pathology Histology
and Tissue Core Facility. Immunohistochemical staining was
performed as previously described [70] or as specified by
manufacturer guidelines (Sigma). The results were scored by
neuropathologists according to standard clinical criteria, and
images of RIOK2 immunoreactivity were taken on an Olympus
DP72.
Mouse intracranial graft assays
For orthotopic implantation of mouse astrocytes engineered in
vitro, low passage cells (no more than 8–10 passages) were used in
two separate experiments. 16105 cells in 5 ml of PBS were injected
stereotactically 2 mm lateral to the midline and 1 mm anterior to
the bregma into the brains of 5–6 week old athymic nu/nu mice.
Mice were monitored and all animals were sacrificed upon
evidence of neurological symptoms in experimental groups such
that all samples were time-matched. Brains were removed for
processing and histological analysis. Sections were scored inde-
pendently by two neuropathologists for the presence of tumors and
injection-associated needle scars. Animals injected with RIOK2-
expresing cells that developed tumors outside of the brain (n = 1)
were excluded from the final tally. All animal experiments were
approved and conducted according to animal welfare guidelines of
the IACUC at the University of California, San Diego.
Supporting Information
Figure S1 DEGFR signaling drives glial neoplasia. (A) Optical
projections of whole brain-ventral nerve cord complexes from late
3rd instar larvae, approximately 130 hrs old, displayed at the same
scale. Genotypes matched to those displayed in close-ups in B–G.
Dorsal view; anterior up. Glia are labeled with GFP (green) driven
by repo-Gal4. (B–G) 3 mm optical projections of brain hemispheres
from late 3rd instar larvae, displayed at the same scale. Frontal
sections, midway through brains. Anterior up; midline to left. Glial
cell nuclei labeled with Repo (red); glial cell bodies labeled with
GFP (green). Brains counter-stained with anti-HRP (blue), which
reveals neuropil at high intensity and neuronal cell bodies at low
intensity. (B, C) glial-specific overexpression of DEGFR in the
larval brain induced excess glial cell numbers, brain enlargement,
and lethality that was rescued with gefitinib (A, F, H). Co-
overexpression of DEGFR with dp110CAAX produced lethal
neoplasia, very similar to that of dEGFRl;dp110CAAX animals, that
was partially suppressed by gefitinib treatment (A, D, G).
However, gefitinib treatment did not fully suppress the growth
of neoplastic DEGFR; dp110CAAX glia nor did it rescue lethality
caused by DEGFR; dp110CAAX overexpression (G, H).
(TIF)
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Figure S2 Classification of EGFR; PI3K modifiers. (A) Ven
diagram comparing confirmed modifiers from this screen to other
relevant RNAi-screens in Drosophila and to orthologous human
kinases implicated in GBM, individual kinases noted in Table S6.
(B, C) Network diagrams adapted from STRINGS showing
functional connections between Drosophila modifier kinases (B), and
functional connections between modifier kinases according to
orthology information using COG (Clusters of Orthologous
Groups) analysis (C) [26]. Confidence views of networks are
presented such that stronger associations are represented by
thicker lines. Orthologs of kinases implicated in GBM are shown
in black, novel modifiers are shown in green (suppressors) and in
red (enhancers). Many of the novel modifiers do not have
established functional links to RTK or PI3K signaling in Drosophila
(B). When network analysis takes into account datasets from
orthologous kinases in other organisms, such as yeast (C), several of
the novel modifiers show connections with each other and with
other categorized modifiers of RTK and PI3K signaling,
suggesting that these novel modifiers represent new pathway
components.
(TIF)
Figure S3 Expression of human orthologs of modifier kinases in
high-grade human gliomas. (A–F) Representative immunohisto-
chemical stains for each indicated protein performed on high-
grade malignant glioma tumor tissue, all done as part of the
Human Protein Atlas Project. CDK7 and CDK9 are nuclear
proteins, and show enriched immunoreactivity in tumor cells.
TNK2 and RIOK2 are known or predicted cytoplasmic proteins.
Antibodies were extensively validated as described in HPA [73],
and this data is available at www.proteinatlas.org. Immunostains
for each protein were performed on panels of 10–24 tumors, and
this data is summarized in Table S10.
(TIF)
Figure S4 Expression of modifier orthologs in cultured GBM
cells expressing DEGFR. U87MG and U87MG-DEGFR cells
were cultured with .1% serum for 36 hrs to isolate DEGFR
signaling, and their extracts were immunobloted for indicated
proteins. DEGFR runs below full-length EGFR. Proteins that
show upregulation in U87MG-DEGFR cells are each indicated
with arrows.
(TIF)
Figure S5 RIO kinase expression in a panel of GBM cell lines.
Indicated cell lines were cultured with .1% serum for 36 hrs to
reduce expression artifacts from serum treatment, and their
extracts were immunobloted for indicated proteins. PTEN mutant
status is shown; SF767 is documented to be PTEN wild-type, while
all others have been documented to be PTEN protein null mutant.
(TIF)
Figure S6 p110 and Akt inhibition, but not mTor inhibition,
alters RIOK2 expression. (A) U87MG (parent) compared to
U87MG-DEGFR cells, cultured in .1% serum and treated for
48 hrs with DMSO, 500 nM BEZ-235, or 2 mM PI-103, or
treated for 24 hrs with DMSO or 1 mMA443654. PI3K inhibition
by BEZ-235 and PI-103 shown by reduced Akt phosphorylation at
Serine-473; the blot for Akt-Ser473 phosphorylation has been
overexposed to highlight the degree of inhibition of PI3K signaling
by BEZ-235 and other compounds rather than the differences in
Akt-Ser473 phosphorylation between U87MG and U87MG-
DEGFR (see Figure 2A). (B) U87MG compared to U87MG-
DEGFR cells, cultured in .1% serum and treated for 24 hrs with
DMSO (both U87MG and U87MG-DEGFR), 1 nM rapamycin,
or 2 mM PP242, which is an inhibitor of mTor kinase activity.
Inhibition of mTor kinase activity is evident by reduced Akt
phosphorylation at Serine-473 and/or reduced 4E-BP1 phosphor-
ylation. Increased 4E-BP1 phosphorylation was induced by
rapamycin treatment, likely due to positive feedback [74]. RIOK2
is clearly elevated in the presence of EGFR, and is not decreased
upon mTor inhibition. RIOK1 shows some reduction with PP242
treatment, but less so with rapamycin treatment.
(TIF)
Figure S7 Akt signaling regulates RIO kinase protein stability.
(A) U87MG-DEGFR cells were infected with retroviruses
containing PTEN, PTEN-G129R (catalytically inactive), or empty
vector. Cells were serum-starved for 48 hours and treated for
8 hours with 10 mM MG132, a proteosomal inhibitor. Reduced
Akt phosphorylation at Serine-473 is evidence of inhibition by
PTEN. (B, C) U87MG-DEGFR (B) cells or GBM301 (C) cells were
treated with DMSO or 2 mM A443654 with and without 10 mM
MG132 for 10 hrs. Akt inhibition is evidenced by reduced
PRAS40 phosphorylation in A443664 treated samples.
(TIF)
Figure S8 RIOK2 motif scan. The RIOK2 protein sequence
was examined with the Scansite Motif Scanner (http://scansite.
mit.edu/motifscan_seq.phtml) [75]. The kinase domain, which is
highly similar to that of RIOK1 (RIO1), is indicated in blue.
Potential phosphorylation sites are indicated by residue, and lower
scores indicate that the predicted site falls into the top percentiles
set by high stringency. Serine-483 in RIOK2 has been confirmed
as a site of phosphorylation by several unpublished proteomic
analyses available at PhosphoSitePlus (http://www.phosphosite.
org) [76].
(TIF)
Figure S9 Potential phosphorylation of RIOK2 by Akt.
Epitope-tagged RIOK2 (RIOK2-flag) was immunoprecipitated
and detected by antibodies specific to Akt substrates phosphory-
lated on serine or threonine at characteristic Akt target sites
(RXXS/T). RIOK2-KD-S483A-flag is an epitope tagged mutant
form of RIOK2 which contains a serine-to-alanine change in
Serine-483, which is a candidate Akt phosphorylation site (see
Figure S8) and two point mutations that render RIOK2 kinase
dead to block potential autophosphorylation [18]. Mutation of
Serine-483 and the kinase domain did not block the ability of the
Akt substrate antibody to detect RIOK2, indicating that other
phosphorylation sites in RIOK2 are also recognized by the
antibody.
(TIF)
Figure S10 RIOK2 expression in the giant cell and pseudo-
pallisade fractions of GBM tumors. Immunohistochemical staining
for RIOK2 (reddish brown), with hematoxilin counterstain. Wider
views of heterogeneous RIOK2 immunoreactivity in DEGFR-
positive human GBMs with giant cell components (A, B), cropped
section of A also shown in Figure 4B. Wider view showing RIOK2
immunoreactivity in pseudopallisades (C), also shown cropped in
Figure 4D, with high magnification (D) to show enrichment for
RIOK2 present in the cellular fraction of pseudopallisades.
(TIF)
Figure S11 Akt and EGFR in GBM tumor tissues positive for
RIOK2 expression. Immunohistochemical stains for EGFR and
Akt done on sections from the same tumor samples stained for
RIOK2 in Figure 4B/Figure S10A (A) and Figure 4E (B). Both
tumors show strong expression of EGFR and phosphorylated Akt
(Akt-S473-P).
(TIF)
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Figure S12 WST1 proliferation assays reveal a requirement for
modifier kinases in GBM cells. (A–C) WST-1 assays performed on
U87MG cells for indicated genes. Following selection for shRNA
expression, proliferation was measured with WST-1 reagent and
quantified as the fold increase in absorbance between day 0 and
day 3, normalized to controls treated with a nontargeting shRNA.
2–3 shRNAs tested per kinase. P values refer to one-way ANOVA
with Dunnett post test.
(TIF)
Figure S13 RIOK knockdown verification for Figure 5. (A, B)
Verification of RIOK1 and RIOK2 knockdown in U87MG (A)
and U87MG-DEGFR (B) cells treated with the indicated shRNAs
and subjected to WST1 assays as shown in Figure 5A (left panels).
(C) Verification of RIOK2 knockdown in LNZ308 (C) cells treated
with the indicated shRNAs and subjected to WST1 assays as
shown in Figure 5A (right panel). (D, E) Verification of RIOK1
and RIOK2 knockdown in U87MG (D) and LNZ308 (E) cells
treated with the indicated siRNAs and subjected to FACS analysis
for cell cycle progression as shown in Figure 5B. (F) Upregulation
of p53 upon RIOK2 knockdown with shRNAs. (G) Verification of
p53 knockdown in U87MG cells treated with siRNAs against p53
and the RIOKs and subject to FACS analysis of apoptosis as
shown in Figure 5E.
(TIF)
Figure S14 Loss of RIOK1 and RIOK2 induces L11-dependent
p53 upregulation. RIOK1 or RIOK2 knockdown upregulates p53
and p21 expression in A712 (A) and U178 (B) GBM cells, which is
blocked by concurrent RpL11 knockdown. A172 cells are PTEN-
mutant and EGFR-mutant, U178 cells are PTEN-mutant, and
both are wild-type for p53 [38,39,50]. For RpL11 co-knockdown
experiments, cells were treated with equivalent amounts of siRNAs
mixed 1:1 for all control and experimental samples. Cells were
harvested 72 hrs post-transfection with siRNAs.
(TIF)
Figure S15 RIOK loss chemosensitizes GBM cells. Represen-
tative scatter plots of FACS-based quantification of chemosensi-
tivity. U87MG cells were treated with 1 mg/mL doxorubicin and
100 mM temozolomide for 12 hrs beginning 96 hrs post shRNA
infection. Treated cells were collected and stained live for 7AAD
and Annexin-V. 7AAD alone identifies dead cells (Q1). Annexin V
identifies cells in early apoptosis when alone (Q4) and in late stage
apoptosis when coincident with 7AAD (Q2). Viable cells (Q3)
stained for neither. The percentage of Annexin-V-positive cells
present upon doxorubicin and temozolomide treatment signifi-
cantly increased in RIOK1-shRNA and RIOK2-shRNA treated
cells compared to cells treated with a non-targeting control
shRNA.
(TIF)
Figure S16 Nutlin-3 treatment does not phenocopy RIOK2
loss. (A) U87MG cells treated with 10 mM nutlin-3 (red) or DMSO
(control, black) for 48 hrs prior to fixation and propidium iodide
staining for DNA content for cell cycle analysis by FACS. (B)
Immunnoblot showing that nutlin-3 treatment significantly
increased p53 and p21 levels in U87MG cells, as compared to
both control cells and siRNA-RIOK2 treated cells. (C) GBM301
cells plated adherently and infected with a GFP control lentivirus
(left panel) or an shRNA lentivirus targeting RIOK2 (right panel).
Brightfield images taken 96 hrs post-infection. RIOK2 protein
levels drop starting about 72 hrs post-infection, such that 96 hrs is
equivalent to 24 hrs of knockdown. Adherent GBM301 cells
treated with 10 mM nutlin-3 for 24 hrs (middle panel). Nutlin-3
largely decreased growth of GBM301 cells, whereas RIOK2
knockdown more prominently stimulated apoptosis, yielding many
pyknotic and vacuolated cells.
(TIF)
Figure S17 Loss of RIOK1 and RIOK2 function reduces
TORC2-Akt signaling. (A) GBM6, a DEGFR-positive and p53
mutant neurosphere line. RIOK1 or RIOK2 knockdown caused
reduced phosphorylation of Akt on the TORC2 target site, Serine-
473, which is clear relative to total Akt protein. Cells harvested 5
days post-infection with viral vectors that target RIOK1/2 or a
control vector, treated with 25 mM ZVAD for 48 hrs prior to
harvest. (B) RIOK1 knockdown caused reduced phosphorylation
of Akt on Serine-473 in U87MG-DEGFR cells. Reduced
phosphorylation of FOXO3 at the TORC2-dependent Akt target
site was detected upon RIOK1 knockdown. Cells harvested 5 days
post-infection with viral vectors that target RIOK1/2 or a control
vector, treated with 25 mM ZVAD for 48 hrs prior to harvest. (C)
RIOK2 knockdown caused reduced phosphorylation of Akt on
Serine-473 in U87MG cells. RIOK2 knockdown was also
associated with reduced phosphorylation of NDRG1, aTORC2
read-out, and increased p53 protein levels. Cells treated with
nontargeting control siRNAs or RIOK2 siRNAs, harvested 96 hrs
post-transfection.
(TIF)
Figure S18 Expression of RIOK2 in other tumor types. (A–F)
Representative immunohistochemical stains for RIOK2 per-
formed on malignant tumor tissue, all done as part of the Human
Protein Atlas Project [73]. (A) breast cancer (duct carcinoma), (B)
lung cancer (squamous cell carcinoma), (C) colorectal cancer
(adenocarcinoma), (D) head and neck cancer (squamous cell
carcinoma), (E) prostate cancer (adenocarcinoma), and (F)
malignant melanoma. RIOK2 showed strong expression in 92–
100% of colon and head and neck tumors examined, in 50–58%
of lung, prostate, and melanoma tumors examined, and in 25% of
breast tumors examined (complete analysis and images available at
www.proteinatlas.org).
(TIF)
Table S1 All kinases in the Drosophila genome. Kinases that are
confirmed hits in the dEGFRl;dp110CAAX screen are in bold,
kinases not tested due to lack of available constructs are in grey
italics.
(XLS)
Table S2 Screen results from all UAS-dsRNA stocks tested.
VDRC stock ID numbers prefaced by ‘‘v,’’ Blooming stock ID
numbers prefaced by ‘‘b,’’ NIG stock ID numbers prefaced by an
‘‘n,’’ TRIP stock numbers prefaced with a ‘‘t.’’ Bold highlights all
stocks that yielded reproducible genetic interactions and clear
phenotypic alterations. Genes that are considered confirmed hits
have multiple UAS-dsRNA stocks listed in bold and are highlighted
in yellow. Key to genetic interactions: N: no interaction/no
difference, WS: weak suppressor, S: moderate suppressor, SS:
strong suppressor, WE: weak enhancer, E: moderate enhancer,
SE: strong enhancer. ‘‘?’’ denotes interactions that were milder
than the ‘‘weak’’ designation but subtly different from controls.
(XLS)
Table S3 Dominant negative constructs, overexpression con-
structs, and mutant alleles tested. Blooming stock ID numbers
prefaced by ‘‘b.’’ Bold highlights all confirmed stocks that yielded
reproducible genetic interactions and clear phenotypic alterations.
Key to genetic interactions: N: no interaction/no difference, WS:
weak suppressor, S: moderate suppressor, SS: strong suppressor,
WE: weak enhancer, E: moderate enhancer, SE: strong enhancer.
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‘‘?’’ denotes interactions that were milder than the ‘‘weak’’
designation but subtly different from controls.
(XLS)
Table S4 Testing modifier kinase RNAi constructs in wild-type
glia, neuroblasts, neurons, and eye epithelia. VDRC stock ID
numbers prefaced by ‘‘v,’’ Blooming stock ID numbers prefaced
by ‘‘b,’’ NIG stock ID numbers prefaced by ‘‘n.’’ Not all stocks
tested in all assays. Bold highlights all confirmed dEGFRl;
dp110CAAX modifier stocks that yielded reproducible genetic
interactions. Key to dEGFRl; dp110CAAX genetic interactions: N:
no interaction, WS: weak suppressor, S: moderate suppressor, SS:
strong suppressor, WE: weak enhancer, E: moderate enhancer,
SE: strong enhancer. ‘‘?’’ denotes interactions that were marginal.
Testing in wild-type neuroblasts and neurons (26 wor-Gal4, elav-
Gal4) was done with UAS-dcr in the background to potentiate
RNAi. Data from RNAi constructs tested in neuroblasts with insc-
Gal4 derived from http://neuroblasts.imba.oeaw.ac.at 1. ‘‘Le-
thal,’’ ‘‘semi-lethal,’’ and ‘‘viable’’ refer to whole-animals effects of
modifier constructs in an otherwise wild-type background. In glial-
specific assays, whole animal lethality indicates that the genes in
question may be essential for some aspect of normal glial function
or development, but not necessarily for glial proliferation as
blocking glial proliferation is not lethal. For analysis of larval glia,
fixed specimens were stained for glial cell nuclei/numbers and
viewed at higher magnification.
(XLS)
Table S5 DEGFR and DEGFR;dp110CAAX modifiers, listed by
stocks tested. VDRC stock ID numbers prefaced by ‘‘v.’’ Bold
highlights all confirmed stocks that yielded reproducible genetic
interactions and clear phenotypic alterations. Genes that are
considered ‘confirmed hits’ in the initial screen are listed in bold.
Key to genetic interactions: N: no interaction/no difference, WS:
weak suppressor, S: moderate suppressor, SS: strong suppressor,
WE: weak enhancer, E: moderate enhancer, SE: strong enhancer.
(XLSX)
Table S6 Human orthologs and functional classification of
confirmed dEGFRl;dp110CAAX modifier kinases. Orthologs were
curated from http://kinase.com/ and names for each were
updated according to current Gene ID numbers and NCBI
annotations. GO terms from GOEast, http://omicslab.genetics.
ac.cn/GOEAST/.
(XLS)
Table S7 Overlap with related RNAi screens in Drosophila and
human systems. Novel modifier genes not previously implicated in
glioblastoma are highlighted in green (suppressors) and red
(enhancers). *Drosophila genes that did not emerge from the annotated
RNAi screens, but that have well established roles in RTK and PI3K
signaling and/or cell proliferation and survival in vivo.
(XLS)
Table S8 Human Orthologs for novel modifiers of
dEGFRl;dp110CAAX. Orthologs were curated from http://
kinase.com/ and names for each were updated to current NCBI
annotations. Human kinases selected for study in human GBM
model systems are in bold, as are their Drosophila counterparts.
(XLS)
Table S9 TCGA Microarray data for human orthologs of novel
modifiers. Each value is AgilentG4502A_07 log2 tumor/normal
ratio taken from TCGA profiling, found at http://tcga-portal.nci.
nih.gov/tcga-portal/AnomalySearch.jsp. Significant overexpres-
sion of 3-fold or more (.1.5) is noted in pink. Significantly
decreased expression is noted in blue. Average expression for each
gene for all samples is noted at the base of the table. Average
expression with standard deviation for each gene for EGFR-
overexpressors is noted at the base of the table.
(XLSX)
Table S10 Summary of Human Protein Atlas data adapted from
www.proteinatlas.org. Genes highlighted in italics show notable
upregulation in the indicated cells and tissues, as assessed by IHC.
(XLSX)
Text S1 Supplemental Results and Materials and Methods.
Additional detail on validation of novel kinases in mammalian
systems, screening methodology, and shRNA and siRNA sequenc-
es.
(DOC)
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